Naringenin suppresses NLRP3 inflammasome activation via the mRNA-208a signaling pathway in isoproterenol-induced myocardial infarction

Abstract

Objective: To investigate the cardioprotective effect of naringenin against isoproterenol (ISO)-induced cardiotoxicity in rats. Methods: Rats were divided into five groups: the normal group, the ISO group (85 mg/kg b.w.); the ISO+naringenin (50 mg/kg b.w.) group, the ISO+naringenin (100 mg/kg b.w.) group and the ISO+propranolol (10 mg/kg b.w.) group. Plasma creatine kinase-MB (CK-MB), cardiac troponin T, lactate dehydrogenase, brain natriuretic peptide (BNP), and IL-10, as well as cardiac transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF) and malondialdehyde (MDA) were examined. In addition, NLRP3 and mRNA-208a expressions were evaluated by RT-PCR analysis. Histopathological examination was also performed to assess cardiac damages. Results: Naringenin treatment significantly decreased plasma lactate dehydrogenase, CK-MB, cardiac troponin T, BNP, and IL-10, as well as cardiac TGF-β1, VEGF, and MDA while increasing p-Akt and superoxide dismutase in ISO-administered rats. It also reduced NLRP3 and mRNA-208a gene expression levels. Furthermore, naringenin improved ISO-induced cardiac damage. Conclusions: Naringenin attenuates myocardial dysfunction in ISO-treated rats by decreasing oxidative stress and increasing cardiac endogenous antioxidant system, which may be modulated partly by improvement of NLRP3 and mRNA-208a gene expression.

Keywords

Naringenin / Isoproterenol / Myocardial infarction / Antioxidants / NLRP3 / mRNA-208a

Conflict of interest statement

The authors declare that they have no conflict of interest.

Funding

The authors received no extramural funding for the study.

Data availability statement

The data supporting the findings of this study are available from the corresponding authors upon request.

Authors’ contributions

The experimental plan for the study was influenced by all authors. MAH was responsible for experimental design and animal grouping. Biochemical, molecular and histological evaluations were conducted by AE and TH. ELISA and PCR examinations were done by AAA and SAE. The protocol, the first version of the article, research analysis, and literature searches were all performed collaboratively by all authors.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Namkhah Z, Naeini F, Mahdi Rezayat S, Mehdi Yaseri, Mansouri S, Javad Hosseinzadeh-Attar M. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial. Int J Clin Pract 2021; 75(11): e14852. doi: 10.1111/ijcp.14852.

[2] Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Yaseri M, et al. Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: A pilot double-blind, placebo-controlled, randomized clinical trial. Eur J Gastroenterol Hepatol 2022; 34(3): 345-353.

[3] Li Y, He B, Zhang C, He Y, Xia T, Zeng C. Naringenin attenuates isoprenaline-induced cardiac hypertrophy by suppressing oxidative stress through the AMPK/NOX2/MAPK signaling pathway. Nutrients 2023; 15(6): 1340. doi: 10.3390/nu15061340.

[4] Chen X, Wan W, Ran Q, Ye T, Sun Y, Liu Z, et al. Pinocembrin mediates antiarrhythmic effects in rats with isoproterenol-induced cardiac remodeling. Eur J Pharmacol 2022; 920: 174799. doi: 10.1016/j.ejphar.2022.

[5] Hoff R, Koh CK. Isoproterenol induced insulin resistance leading to diabetic ketoacidosis in type 1 diabetes mellitus. Case Rep Endocrinol 2018; 2018. doi: 10.1155/2018/4328954.

[6] Baraka SA, Tolba MF, Elsherbini DA, El-Naga RN, Awad AS, El-Demerdash E. Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. Clin Exp Pharmacol Physiol 2021; 48(10): 1358-1370.

[7] Yue M, Shao L, Cheng J, Fan Y, Cai X, Li H, et al. Prostaglandin E₂ accelerated recovery of chemotherapy-induced intestinal damage by increasing expression of cyclin D . Exp Cell Res 2020; 388(2). doi: 10.1016/j.yexcr.2020.111819.

[8] Hu JN, Yang JY, Jiang S, Zhang J, Liu Z, Hou JG, et al. Panax quinquefolium saponins protect against cisplatin evoked intestinal injury via ROS-mediated multiple mechanisms. Phytomedicine 2021; 82. doi: 10.1016/j.phymed.2020.153446.

[9] Fang Z, Liu Z, Tao B, Jiang X. Engeletin mediates antiarrhythmic effects in mice with isoproterenol-induced cardiac remodeling. Biomed Pharmacother 2023; 161. doi: 10.1016/j.biopha.2023.

[10] Shanmugam G, Challa AK, Litovsky SH, Devarajan A, Wang D, Jones DP, et al. Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice. Redox Biol 2019; 27. doi: 10.1016/j.redox.2019.101212.

[11] Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Jazayeri-Tehrani SA, et al. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: Study protocol for a randomized double-blind clinical trial. Trials 2021; 22(1): 801. doi: 10.1186/s13063-021-05784-7.

[12] López-Almada G, Domínguez-Avila JA, Mejía-León ME, Robles-Sánchez M, González-Aguilar GA, Salazar-López NJ. Could naringenin participate as a regulator of obesity and satiety? Molecules 2023; 28(3): 1450. doi: 10.3390/molecules28031450.

[13] Li M, Liu Y, Weigmann B. Biodegradable polymeric nanoparticles loaded with flavonoids: A promising therapy for inflammatory bowel disease. Int J Mol Sci 2023; 24(5). doi: 10.3390/ijms24054454.

[14] Joshi R, Laddha AP, Kulkarni YA, Wairkar S. Improved performance of naringenin herbosomes over naringenin in streptozotocin-induced diabetic rats: In vitro and in vivo evaluation. Asian Pac J Trop Biomed 2021; 11(9): 385-393.

[15] Joshi R, Kulkarni YA, Wairkar S. Pharmacokinetic, pharmacodynamic and formulations aspects of naringenin: An update. Life Sci 2018; 215: 43-56.

[16] Zobeiri M, Belwal T, Parvizi F, Naseri R, Farzaei MH, Nabavi SF, et al. Naringenin and its nano-formulations for fatty liver: Cellular modes of action and clinical perspective. Curr Pharm Biotechnol 2018; 19: 196-205.

[17] Massaro L, Raguzzini A, Aiello P, Valencia DV. The potential role of naringin and naringenin as nutraceuticals against metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2023; 23(4): 428-445.

[18] Memariani Z, Abbas SQ, Ul Hassan SS, Ahmadi A, Chabra A. Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review. Pharmacol Res 2021; 171. doi: 10.1016/j.phrs.2020.105264.

[19] Rauf A, Shariati MA, Imran M, Bashir K, Khan SA, Mitra S, et al. Comprehensive review on naringenin and naringin polyphenols as a potent anticancer agent. Environ Sci Pollut Res Int 2022; 29(21): 31025-31041.

[20] Prakash O, Singh R, Singh N, Usmani S, Arif M, Kumar R, et al. Anticancer potential of naringenin, biosynthesis, molecular target, and structural perspectives. Mini Rev Med Chem 2022; 22(5): 758-769.

[21] Duda-Madej A, Stecko J, Sobieraj J, Szymańska N, Kozłowska J. Naringenin and its derivatives-health-promoting phytobiotic against resistant bacteria and fungi in humans. Antibiotics (Basel) 2022; 11(11): 1628. doi: 10.3390/antibiotics11111628.

[22] Kalam MN, Rasool MF, Rehman AU, Ahmed N. Clinical pharmacokinetics of propranolol hydrochloride: A review. Curr Drug Metab 2020; 21(2): 89-105.

[23] Szpunar M, Vanderloo LM, Bruijns BA, Truelove S, Burke SM, Gilliland J, et al. Children and parents’ perspectives of the impact of the COVID-19 pandemic on Ontario children’s physical activity, play, and sport behaviours. BMC Public Health 2021; 21: 2271.

[24] Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I. Population pharmacokinetics and pharmacodynamics of oral propranolol in pediatric patients with infantile hemangioma. J Clin Pharmacol 2018; 58(10): 1361-1370.

[25] Del Frari L, Léauté-Labrèze C, Guibaud L, Barbarot S, Lacour JP, Chaumont C, et al. Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations. Pharmacol Res Perspect 2018; 6(3). doi: 10.1002/prp2.399.

[26] Khan V, Sharma S, Bhandari U, Ali SM, Haque SE. Raspberry ketone protects against isoproterenol-induced myocardial infarction in rats. Life Sci 2018; 194: 205-212.

[27] Hermenean A, Ardelean A, Stan M, Hadaruga N, Mihali CV, Costache M, et al. Antioxidant and hepatoprotective effects of naringenin and its β-cyclodextrin formulation in mice intoxicated with carbon tetrachloride: A comparative study. J Med Food 2014; 17(6): 670-677.

[28] Kakkar P, Das B, Visvanathan P. A modified spectrophotometric assay of SOD. Indian J Biochem Biophys 1984; 21: 130-132.

[29] Bancroft GD, Steven A. Theory and practice of histological technique. 4th ed. Churchill Livingstone, New York; 1983, p. 99-112.

[30] Dhaibar HA, Kamberov L, Carroll NG, Amatya S, Cosic D, Gomez-Torres O, et al. Exposure to stress alters cardiac gene expression and exacerbates myocardial ischemic injury in the female murine heart. Int J Mol Sci 2023; 24(13). doi: 10.3390/ijms241310994.

[31] Elneklawi MS, Mohamed ZN, Hussein MA, Mohamad EA. STEN ameliorates VEGF gene expression by improving XBP1/mRNA-21/mRNA-330 signalling pathways in cisplatin-induced uterus injury in rats. J Drug Deliv Sci Technol 2023; 87. 10.1016/j.jddst.2023.104760.

[32] Mohamad EA, Mohamed ZN, Hussein MA, Elneklawi MS. GANE can improve lung fibrosis by reducing inflammation via promoting p38MAPK/TGF-β1/NF-κB signaling pathway downregulation. ACS Omega 2022; 7(3): 3109-3120.

[33] Mosaad YO, Hussein MA, Ateyya H, Mohamed AH, Ali AA, Ramadan Youssuf A, et al. Vanin 1 gene role in modulation of iNOS/MCP-1/TGF-β1 signaling pathway in obese diabetic patients. J Inflamm Res 2022; 15: 6745-6759.

[34] Elgizawy HA, Ali AA, Hussein MA. Resveratrol: Isolation, and its nanostructured lipid carriers, inhibits cell proliferation, induces cell apoptosis in certain human cell lines carcinoma and exerts protective effect against paraquat-induced hepatotoxicity. J Med Food 2021; 24(1): 89-100.

[35] Nagarajan A, Doss VA. L-carvone attenuates myocardial injury and dyslipidemia in rats with isoproterenol-induced cardiac hypertrophy. Asian Pac J Trop Biomed 2023; 13(1): 17-25.

[36] Wang XP, Wang PP, Bai JQ, Gao S, Wang YH, Quan LN, et al. Investigating the effects and possible mechanisms of danshen-honghua herb pair on acute myocardial ischemia induced by isoproterenol in rats. Biomed Pharmacother 2019; 118. doi: 10.1016/j.biopha.2019.109268.

[37] Chen W, Liang J, Fu Y, Jin Y, Yan R, Chi J, et al. Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats. Ann Transl Med 2020; 8(6): 309. doi: 10.21037/atm.2020.02.93.

[38] Zhang YF, Meng NN, Li HZ, Wen YJ, Liu JT, Zhang CL, et al. Effect of naringin on oxidative stress and endoplasmic reticulum stress in diabetic cardiomyopathy. Zhongguo Zhong Yao Za Zhi 2018; 43(3): 596-602.

[39] Wang Y, Zhang X, Gao L. Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang Ⅱ through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways. Ann Transl Med 2019; 7: 561. doi: 10.21037/atm.2019.09.45.

[40] El Gizawy HA, Abo-Salem HM, Ali AA, Hussein MA. Phenolic profiling and therapeutic potential of certain isolated compounds from Parkia roxburghii against AChE activity as well as GABAAα5, GSK-3β, and p38α MAP-kinase genes. ACS Omega 2021; 6(31): 20492-20511.

[41] Soliman SM, Mosallam S, Mamdouh MA, Hussein MA, Abd El-Halim SM. Design and optimization of cranberry extract loaded bile salt augmented liposomes for targeting of MCP-1/STAT3/VEGF signaling pathway in DMN-intoxicated liver in rats. Drug Deliv 2022; 29(1): 427-439.

[42] Hussein MA, Ismail NEM, Mohamed AH, Borik RM, Ali AA, Mosaad YO. Plasma phospholipids: A promising simple biochemical parameter to evaluate COVID-19 infection severity. Bioinform Biol Insights 2021; 15. doi: 10.1177/11779322211055891.

[43] Borik RM, Hussein MA. Synthesis, molecular docking, biological potentials and structure activity relationship of new quinazoline and quinazoline-4-one derivatives. Asian J Chem 2021; 33(2): 423-438.

[44] Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 2020; 11: 2127.

[45] Jain PG, Mahajan UB, Shinde SD, Surana SJ. Cardioprotective role of FA against isoproterenol induced cardiac toxicity. Mol Biol Rep 2018; 45(5): 1357-1365.